Skin side-effects of elexacaftor-tezacaftor-ivacaftor: a real-world view [0.03%]
尤林卡福尔特-泰扎福尔特-伊瓦卡拉夫托对皮肤的副作用：真实世界观点
Sophie Constantinou,Lucy Webber,Alice Darby et al.
Sophie Constantinou et al.
Background: Since 2020, ETI (elexacaftor/tezacaftor/ivacaftor) has been used to treat patients with cystic fibrosis. Acne and rash are listed as "common" and "very common" adverse effects in the Summary of Product Charact...
Diffuse infiltrative lymphocytic syndrome in recently diagnosed HIV patient: a case-report DILS-ILD responsive to steroids [0.03%]
新诊断HIV患者发生弥漫性浸润性淋巴细胞综合征1例及激素治疗反应报告(DILS-ILD)
Nicolas Duhamel,Pierre-Yves Jeandel,Marie Ottavi et al.
Nicolas Duhamel et al.
Prevalence and incidence of adult bronchiectasis in Hong Kong from 2008-2023: A population-based cohort study [0.03%]
2008-2023年香港成人支气管扩张患病率和发病率的人群队列研究
ZhiLing Yuan,Philip Cm Au,Ching Lung Cheung et al.
ZhiLing Yuan et al.
While the incidence and prevalence of bronchiectasis was reported to be increasing in different parts of the world, the epidemiological data on adult bronchiectasis in Hong Kong is lacking. We aim to investigate the incidence and prevalence...
Prognostic value of the mini nutritional assessment short-form and SpO₂/FiO₂ ratio at admission for in-hospital mortality in patients with interstitial lung disease [0.03%]
入院时营养状况和氧合功能评分对间质性肺疾病住院患者病死率的预后价值分析
Mayuko Ishiwari,Yuta Kono,Yuki Togashi et al.
Mayuko Ishiwari et al.
Background: Hospitalization of patients with interstitial lung disease (ILD) is a poor prognostic factor. Simple and rapid biomarkers at the time of admission of hospitalized ILD patients are needed. The aim of this study...
Evolving paradigms in pulmonary hypertension: Highlights of the 6th French Pulmonary Hypertension Network Meeting [0.03%]
肺动脉高压的演变观念：第六届法国肺动脉高压网络会议亮点
Athénaïs Boucly,Antoine Beauvais,Thomas Lacoste-Palasset et al.
Athénaïs Boucly et al.
Long-acting muscarinic antagonist versus leukotriene receptor antagonist as additional treatment in uncontrolled asthma patients used inhaled corticosteroids and long-acting β2 adrenergic agonist: a randomized phase 2 screening trial [0.03%]
长效抗胆碱能药物与白三烯受体拮抗剂作为吸入皮质类固醇和长效β2肾上腺素受体激动剂联合控制不佳的哮喘患者的附加治疗：一项随机Ⅱ期筛选试验
Fumiya Nihashi,Kazuki Furuhashi,Mitsuru Niwa et al.
Fumiya Nihashi et al.
Bronchial asthma is a common disease treated primarily with inhaled corticosteroids (ICS) and long-acting beta-2 agonists (LABA), yet optimal add-on therapy with long-acting muscarinic antagonists (LAMA) or leukotriene receptor antagonists ...
Six-minute walking distance is a robust predictor of mortality in stable chronic obstructive pulmonary disease without major comorbidities [0.03%]
6分钟步行距离是无重要并发症的慢性阻塞性肺疾病稳定期患者生存率的强大预测指标
Brede Kvisvik,Ingunn Skjørten,Janne Mykland et al.
Brede Kvisvik et al.
Background: Most patients with COPD are examined with specific pulmonary function tests and blood samples in addition to six-minute walking distance (6MWD), while few are examined by echocardiography and even fewer by inv...
Real-world management of unresectable stage III non-small-cell lung cancer: Impact of durvalumab consolidation therapy in French clinical practice [0.03%]
Durvalumab巩固治疗在法国临床实践中的Ⅲ期不可切除性非小细胞肺癌实际管理的影响
Christos Chouaid,Philippe Giraud,Marie Wislez et al.
Christos Chouaid et al.
Background: Durvalumab consolidation therapy has improved survival after chemoradiotherapy in patients with advanced non-small-cell lung cancer (NSCLC). Our three-cohort study from France described the real-world effectiv...
Addressing the inequities in interstitial lung disease care outside specialised centres in Australia [0.03%]
澳大利亚专科中心外肺间质疾病治疗不平等的问题探讨
Gabriella Tikellis,Anne E Holland
Gabriella Tikellis
Understanding participation challenges in lung cancer screening program: Findings from the DEP'KP80 trial in France [0.03%]
法国DEP'KP80试验中肺癌筛查项目参与障碍的影响因素分析
Sébastien Couraud,Emmanuel Grolleau,Bernard Milleron et al.
Sébastien Couraud et al.
Background: Lung cancer is the leading cause of cancer-related mortality worldwide. Low-dose computed tomography (LDCT) screening can significantly reduce mortality among high-risk populations. However, participation rate...